Business
Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability
"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Pat...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma\n in High Risk CVD Patients\"\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Nov. 4, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) today\n announced two additional results from the ongoing analysis of its Phase\n 2b ASSURE clinical trial using intravascular ultrasound (IVUS) to study\n high-risk cardiovascular disease (CVD) patients for assessing benefits\n of RVX-208.  This lead molecule is a member of a new class of compounds\n that affects cellular epigenetics by specifically inhibiting a BET\n protein leading to enhanced apoA-I gene transcription and the creation\n of functional HDL particles for treating atherosclerotic CVD.  Since\n the completion of the ASSURE trial the continued analysis of the data\n have yielded two new findings that detail the effects of RVX-208 on\n vascular inflammation and virtual histology.\n\n\nFirst, the data showed statistically significant improvements in\n coronary IVUS atheroma measurements and Major Adverse Cardiac Events\n (MACE) in patients with a high (>2.0 mg/dL) serum high sensitivity\n C-Reactive Protein (hsCRP).  Serum levels of this biomarker when >2.0\n mg/dL reflect a heightened state of inflammation that is a well-known\n and major component of CVD risk.  Patients with hsCRP>2.0 mg/dL at time\n of entry into ASSURE totaled n=184 of which n=54 were given placebo\n while n=130 received RVX-208.  In the RVX-208 treated patients, there\n was a 60% reduction (p<0.0001) in hsCRP vs. baseline and (p=0.054) vs.\n placebo. Furthermore atheroma regression was observed in patients\n treated with RVX-208 as measured by percent atheroma volume (PAV), \n total atheroma volume (TAV)  regressed, and the worst 10mm TAV segment\n by  -0.75% (p<0.03), -6.3mm3 (p<0.001) and -2.63mm3 (p<0.001), respectively vs. baseline.  Equally intriguing and perhaps\n more important is that in RVX-208 treated patients with hsCRP>2.0 mg/dL\n the incidence of MACE was lower by 63% (p=0.023) vs. placebo.  The\n preceding observation is of value in that hsCRP of >2.0 mg/dL is well\n known to be clinically important in predicting CVD risk.\n\n\nThe second new observation arises from a pre-specified exploratory\n endpoint in ASSURE gathered using a new catheter (Volcano Revol...